Asset Details
Do you wish to reserve the book?
Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study
Do you wish to request the book?
Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study
2024
Overview
Background
The clinical presentations of Parkinson’s disease (PD), a chronic neurodegenerative condition, include bradykinesia, hypokinesia, stiffness, resting tremor, and postural instability. Recently, neuroinflammation is involved in pathogenesis of PD. Application of nonsteroidal anti-inflammatory drugs captured attention to treat these neuroinflammation.
Aim
To investigate the possible effectiveness of celecoxib in patients with PD treated with conventional treatment.
Methods
Sixty outpatients who fulfilled the inclusion requirements for PD were enrolled in this randomized, prospective, and controlled study. The patients were allocated into two groups at random (
n
= 30); the control group received standard PD treatment, consisting of levodopa/carbidopa, and the celecoxib group received standard PD treatment plus celecoxib. A neurologist evaluated each patient at the beginning of the treatment and after 6 months. Assessment of Unified Parkinson’s disease rating scale (UPDRS) for each patient. Before and after treatment, α -synuclein (α-Syn), tumor necrosis factor alpha (TNF-α), Toll like receptors-4 (TLR-4), nuclear factor erythroid 2–related factor 2 (Nrf-2) and brain-derived neurotropic factor (BDNF) were assessed. Paired and unpaired t tests were used to assess statistical significance within and between groups respectively.
Results
The celecoxib group exhibited a significant and statistical reduction in the level of measured parameters by unpaired t test as followed: TLR-4 (
p
= 0.004), TNF-α (
p
= 0.042), and α-Syn (
p
= 0.004) apart from a significant increase in BDNF (
p
= 0.0005) and Nrf-2 (
p
= 0.004), in comparison with the control group. Also, UPDRS was significantly decreased in celecoxib group (
p
< 0.05).
Conclusion
Celecoxib could be a promising adjuvant therapy in managing patients with PD.
Trial registration number
NCT05962957.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ alpha-Synuclein - metabolism
/ Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
/ Anti-Inflammatory Agents, Non-Steroidal - pharmacology
/ Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
/ Antiparkinson Agents - administration & dosage
/ Antiparkinson Agents - pharmacology
/ Antiparkinson Agents - therapeutic use
/ Biomedical and Life Sciences
/ Brain-Derived Neurotrophic Factor - metabolism
/ Carbidopa - administration & dosage
/ Celecoxib - administration & dosage
/ Drug Repositioning - methods
/ Female
/ Humans
/ Levodopa - administration & dosage
/ Male
/ Parkinson Disease - drug therapy
